Alnylam Pharmaceuticals IncNASDAQ:ALNY
- LAST PRICE144.5800
- TODAY'S CHANGE (%)-0.5800 (-0.3996%)
- Bid / Lots144.4900/ 4
- Ask / Lots144.6700/ 2
- Open / Previous Close144.7200 / 145.1600
- Day Range
- 52 Week Range
- Volume339,199
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALNY |
|---|---|---|
| 09:32 ET | 5658 | 145.48 |
| 09:38 ET | 1200 | 145.54 |
| 09:39 ET | 100 | 145.55 |
| 09:41 ET | 864 | 144.86 |
| 09:43 ET | 400 | 145.79 |
| 09:45 ET | 1808 | 146 |
| 09:48 ET | 2100 | 146.19 |
| 09:50 ET | 753 | 146.26 |
| 09:52 ET | 11100 | 145.92 |
| 09:54 ET | 200 | 145.99 |
| 09:56 ET | 1000 | 146.4 |
| 09:57 ET | 200 | 146.38 |
| 09:59 ET | 800 | 146.87 |
| 10:01 ET | 500 | 146.74 |
| 10:06 ET | 1672 | 146.27 |
| 10:08 ET | 225 | 146.5 |
| 10:10 ET | 200 | 146.24 |
| 10:12 ET | 100 | 146.35 |
| 10:17 ET | 610 | 146.235 |
| 10:19 ET | 1503 | 146.235 |
| 10:21 ET | 1328 | 146.0668 |
| 10:24 ET | 100 | 146.11 |
| 10:26 ET | 200 | 146.095 |
| 10:28 ET | 626 | 146.31 |
| 10:30 ET | 639 | 146.4 |
| 10:35 ET | 200 | 146.575 |
| 10:37 ET | 1055 | 146.405 |
| 10:39 ET | 338 | 146.51 |
| 10:48 ET | 200 | 146.68 |
| 10:50 ET | 1200 | 146.285 |
| 10:51 ET | 1835 | 146.055 |
| 10:53 ET | 100 | 146.11 |
| 10:55 ET | 100 | 146.05 |
| 10:57 ET | 1200 | 146.03 |
| 11:00 ET | 911 | 146.43 |
| 11:02 ET | 400 | 146.49 |
| 11:06 ET | 600 | 145.98 |
| 11:08 ET | 400 | 146.22 |
| 11:09 ET | 200 | 146.32 |
| 11:13 ET | 468 | 146.4 |
| 11:15 ET | 300 | 146.22 |
| 11:18 ET | 400 | 146.105 |
| 11:20 ET | 100 | 146.08 |
| 11:22 ET | 3237 | 146.27 |
| 11:24 ET | 200 | 146.17 |
| 11:26 ET | 100 | 146.23 |
| 11:27 ET | 700 | 146.22 |
| 11:29 ET | 100 | 146.37 |
| 11:31 ET | 971 | 146.395 |
| 11:33 ET | 200 | 146.265 |
| 11:36 ET | 1041 | 146.27 |
| 11:38 ET | 300 | 146.28 |
| 11:42 ET | 1100 | 146.095 |
| 11:44 ET | 300 | 146.03 |
| 11:45 ET | 100 | 146.06 |
| 11:47 ET | 300 | 146.065 |
| 11:49 ET | 2100 | 146.0625 |
| 11:51 ET | 4112 | 146.14 |
| 11:54 ET | 600 | 146.075 |
| 11:56 ET | 700 | 146.04 |
| 11:58 ET | 400 | 146.095 |
| 12:00 ET | 100 | 146.015 |
| 12:02 ET | 400 | 146.13 |
| 12:03 ET | 843 | 146.09 |
| 12:05 ET | 1500 | 146.025 |
| 12:07 ET | 2230 | 146.0125 |
| 12:09 ET | 3400 | 145.985 |
| 12:12 ET | 7300 | 145.7825 |
| 12:14 ET | 1926 | 145.66 |
| 12:16 ET | 7415 | 145.81 |
| 12:18 ET | 4400 | 145.93 |
| 12:20 ET | 2900 | 146.0425 |
| 12:21 ET | 800 | 146.03 |
| 12:23 ET | 3199 | 145.28 |
| 12:25 ET | 500 | 145.2 |
| 12:27 ET | 2739 | 145.24 |
| 12:30 ET | 323 | 145.27 |
| 12:36 ET | 560 | 145.42 |
| 12:38 ET | 206 | 145.365 |
| 12:39 ET | 400 | 145.55 |
| 12:41 ET | 100 | 145.56 |
| 12:43 ET | 800 | 145.7 |
| 12:45 ET | 1545 | 145.85 |
| 12:48 ET | 200 | 145.58 |
| 12:52 ET | 200 | 145.6575 |
| 12:54 ET | 600 | 145.6925 |
| 12:56 ET | 400 | 145.6675 |
| 12:57 ET | 1516 | 145.61 |
| 12:59 ET | 100 | 145.7 |
| 01:01 ET | 200 | 145.53 |
| 01:03 ET | 500 | 145.405 |
| 01:06 ET | 400 | 145.3 |
| 01:10 ET | 700 | 145.235 |
| 01:12 ET | 200 | 145.07 |
| 01:14 ET | 1280 | 145.19 |
| 01:15 ET | 300 | 144.985 |
| 01:17 ET | 200 | 144.955 |
| 01:19 ET | 100 | 144.96 |
| 01:21 ET | 200 | 144.85 |
| 01:24 ET | 700 | 144.875 |
| 01:26 ET | 2100 | 144.855 |
| 01:28 ET | 2399 | 144.25 |
| 01:30 ET | 200 | 144.385 |
| 01:32 ET | 2150 | 144.25 |
| 01:33 ET | 217 | 144.18 |
| 01:35 ET | 5732 | 144.42 |
| 01:39 ET | 540 | 144.28 |
| 01:42 ET | 5589 | 143.9075 |
| 01:44 ET | 100 | 143.81 |
| 01:48 ET | 2154 | 143.73 |
| 01:50 ET | 2400 | 144.12 |
| 01:51 ET | 1100 | 144.21 |
| 01:55 ET | 1600 | 144.025 |
| 01:57 ET | 1600 | 144.05 |
| 02:00 ET | 100 | 143.96 |
| 02:02 ET | 600 | 143.85 |
| 02:04 ET | 200 | 143.74 |
| 02:06 ET | 300 | 143.735 |
| 02:08 ET | 400 | 143.82 |
| 02:09 ET | 1512 | 144.15 |
| 02:11 ET | 700 | 144.12 |
| 02:13 ET | 1100 | 144.145 |
| 02:15 ET | 637 | 144.3 |
| 02:18 ET | 1200 | 144.12 |
| 02:20 ET | 100 | 144.12 |
| 02:22 ET | 1355 | 144.31 |
| 02:24 ET | 1475 | 143.92 |
| 02:27 ET | 200 | 143.8 |
| 02:31 ET | 1700 | 143.645 |
| 02:33 ET | 526 | 143.655 |
| 02:36 ET | 1838 | 143.92 |
| 02:38 ET | 900 | 143.69 |
| 02:40 ET | 300 | 143.53 |
| 02:42 ET | 1503 | 143.52 |
| 02:44 ET | 500 | 143.58 |
| 02:45 ET | 708 | 143.58 |
| 02:47 ET | 1148 | 143.83 |
| 02:49 ET | 100 | 143.92 |
| 02:51 ET | 2907 | 143.5555 |
| 02:56 ET | 800 | 143.52 |
| 02:58 ET | 500 | 143.5 |
| 03:00 ET | 3108 | 143.85 |
| 03:02 ET | 800 | 143.895 |
| 03:03 ET | 800 | 143.955 |
| 03:05 ET | 1100 | 144.185 |
| 03:07 ET | 600 | 144.05 |
| 03:09 ET | 1300 | 144 |
| 03:12 ET | 944 | 144.125 |
| 03:14 ET | 4390 | 144.175 |
| 03:16 ET | 1140 | 144.275 |
| 03:18 ET | 2500 | 144.295 |
| 03:20 ET | 1000 | 144.505 |
| 03:21 ET | 1800 | 144.505 |
| 03:23 ET | 3103 | 144.21 |
| 03:25 ET | 956 | 144.19 |
| 03:27 ET | 11275 | 144.49 |
| 03:30 ET | 2433 | 144.34 |
| 03:32 ET | 1225 | 144.48 |
| 03:34 ET | 600 | 144.54 |
| 03:36 ET | 1774 | 144.59 |
| 03:38 ET | 1800 | 144.58 |
Yesterday
Press Release: Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results, from 8:06AM ET on Thursday Apr 18, 2024 by Dow Jones
8:06AM ET on Thursday Apr 18, 2024 by Dow JonesAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results, from 8:00AM ET on Thursday Apr 18, 2024 by Dow Jones
8:00AM ET on Thursday Apr 18, 2024 by Dow JonesALNY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc., from 7:26AM ET on Thursday Apr 18, 2024 by Dow Jones
7:26AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 17, 2024
Levi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNY, from 7:26AM ET on Wednesday Apr 17, 2024 by Dow Jones
7:26AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 11, 2024
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY, from 7:23AM ET on Thursday Apr 11, 2024 by Dow Jones
7:23AM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alnylam Pharmaceuticals Inc | 18.3B | -40.3x | --- |
Biomarin Pharmaceutical Inc | 17.1B | 101.0x | --- |
Neurocrine Biosciences Inc | 13.3B | 54.1x | +62.04% |
argenx SE | 21.7B | -70.1x | --- |
Medpace Holdings Inc | 11.6B | 41.8x | +35.10% |
Beigene Ltd | 14.5B | -15.3x | --- |
Company Information
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Contact Information
- Headquarters
- 675 W Kendall StCAMBRIDGE, MA, United States 02142-1168
- Phone
- 617-551-8200
- Fax
- 617-551-8101
Executives
- Independent Chairman of the Board
- Amy Schulman
- Chief Executive Officer, Director
- Yvonne Greenstreet
- Chief Financial Officer, Executive Vice President
- Jeffrey Poulton
- Chief Medical Officer, Executive Vice President - Development and Medical Affairs
- Pushkal Garg
- Chief Compliance Officer, Director
- Michael Bonney
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.3B |
|---|---|
Revenue (TTM) | $1.8B |
Shares Outstanding | 125.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-3.59 |
Book Value | $-1.75 |
P/E Ratio | -40.3x |
Price/Sales (TTM) | 10.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
